

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Schlesinger Michael A.</u> (Last) (First) (Middle) C/O ORTHO CLINICAL DIAGNOSTICS HOLDINGS 1001 ROUTE 202 (Street) RARITAN NJ 08869 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Ortho Clinical Diagnostics Holdings plc [OCDX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) EVP, GC and Secretary
	3. Date of Earliest Transaction (Month/Day/Year) 08/11/2021	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares, \$0.00001 par value	08/11/2021		M		72,585	A	\$6.28	160,222	D	
Ordinary Shares, \$0.00001 par value	08/11/2021		S ⁽¹⁾		72,585	D	\$19.7647 ⁽²⁾⁽³⁾	87,637	D	
Ordinary Shares, \$0.00001 par value	08/12/2021		M		8,100	A	\$6.28	95,737	D	
Ordinary Shares, \$0.00001 par value	08/12/2021		S ⁽¹⁾		8,100	D	\$20.0004 ⁽²⁾⁽⁴⁾	87,637	D	
Ordinary Shares, \$0.00001 par value	08/13/2021		M		4,300	A	\$6.28	91,937	D	
Ordinary Shares, \$0.00001 par value	08/13/2021		S ⁽¹⁾		4,300	D	\$20.0007 ⁽²⁾⁽⁵⁾	87,637	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option	\$6.28	08/11/2021		M			72,585	(6)	10/22/2024	Ordinary Shares, \$0.00001 par value	72,585	\$0.00	350,922	D	
Stock Option	\$6.28	08/12/2021		M			8,100	(6)	10/22/2024	Ordinary Shares, \$0.00001 par value	8,100	\$0.00	342,822	D	
Stock Option	\$6.28	08/13/2021		M			4,300	(6)	10/22/2024	Ordinary Shares, \$0.00001 par value	4,300	\$0.00	338,522	D	

Explanation of Responses:

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- The Reporting Person undertakes to provide, upon request by the Securities Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported in this Form 4.
- Represents the weighted average sales price for the price increments ranging from \$19.4800 to \$20.0700.
- Represents the weighted average sales price for the price increments ranging from \$20.0000 to \$20.0050.
- Represents the weighted average sales price for the price increments ranging from \$20.0000 to \$20.0100.
- The stock option is fully vested and exercisable.

Remarks:

/s/ Michael A. Schlesinger 08/13/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.